capecitabine has been researched along with Psoriasis in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Al-Tassan, NA; Cheadle, JP; Escott-Price, V; Houlston, RS; Kaplan, R; Kerr, DJ; Kerr, R; Madi, A; Maughan, TS; Palles, C; Watts, K; Wills, C | 1 |
| Delaney, TA; O'Sullivan, N; Yap, FHX | 1 |
| Diker, O; Dizdar, O; Karakas, Y; Vural, S | 1 |
1 review(s) available for capecitabine and Psoriasis
| Article | Year |
|---|---|
Psoriasis aggravation due to capecitabine: A case study and review of the literature.
Topics: Adenocarcinoma; Capecitabine; Colonic Neoplasms; Disease Progression; Humans; Male; Middle Aged; Prognosis; Psoriasis; Risk Assessment | 2018 |
2 other study(ies) available for capecitabine and Psoriasis
| Article | Year |
|---|---|
Genetic variation in ST6GAL1 is a determinant of capecitabine and oxaliplatin induced hand-foot syndrome.
Topics: Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cetuximab; Colorectal Neoplasms; Diabetes Mellitus, Type 2; Fluorouracil; Genetic Variation; Genome-Wide Association Study; Hand-Foot Syndrome; Humans; Inflammation; Oxaliplatin; Psoriasis; Sialyltransferases | 2022 |
When side effect becomes the effect: Efficacy of capecitabine in refractory psoriasis.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Psoriasis; Skin; Stomach Neoplasms; Treatment Outcome | 2018 |